Changing brand identity: AB-Biotics taps into biotic solutions for eyes and liver

02 May 2023 --- Biotech company AB-Biotics has revealed it is expanding its biotic portfolio to market-ready products for dry eyes and fatty livers and at-home fermenting solutions for consumers. It will showcase its probiotics at Vitafoods in Geneva, Switzerland, next week (May 9-11).

NutritionInsight sits down with Miquel Bonachera and Sergi Audivert, co-founders and executive directors of AB-Biotics, ahead of the company’s attendance at the show.

“We’ll be introducing our new brand identity for the first time. This highlights our portfolio of unique, patented strains with characterized mechanisms of action – premium probiotic solutions targeting specific therapeutic areas and market-ready products.”

“From a clearer market positioning to more identifiable, unique differentiators, we’re excited to bring existing and potential customers and partners through this transition. Visitors can also talk to our experts about the work we’ve been carrying out on probiotics-enriched functional foods, such as fermented juices that bring nutraceutical and food markets together,” they say.

The company will also introduce a new probiotic for fatty livers, which is currently under development. The co-founders describe the preliminary results from the clinical trial as “promising.”

Protears for dry eyes
Bonachera and Audivert highlight another debut from the company, its latest clinical studies on several probiotic blends and postbiotics for dry eyes and fatty livers.

AB-Biotics will also show solutions for consumers to ferment milk at home.They further detail focusing primarily on meeting with individuals interested in AB Biotics as a business and being curious about the science behind probiotics and how the industry is evolving with these capabilities.

“As leaders in the biotics field, it’s our responsibility to educate the industry about the possibilities advanced probiotics solutions offer.”

“In the eye health space, we’ll highlight our Latilactobacillus sakei probio65 (L. sakei probio65) in the ophthalmic bacterial lysate (drops), marketed as AB-PROTEARS. The product is aimed at consumers suffering from dry eye disease symptoms, and our soon-to-be-published clinical trial will be a talking point at the show.”

Entering the market as a medical device, the drops showed the potential to act as artificial tears alleviating symptoms, as well as showing an anti-inflammatory effect on the ocular surface by decreasing cytokine levels.

“Trends come and go”
The co-founders further detail the company’s main focus of production and study of postbiotics.

“This is the heat inactivation of several of our patented probiotic strains and allows customers to expand the use of biotics beyond just supplements and into food matrixes where needed.”

“Here, we launched Dentisani (made up of Streptococcus dentisani), a heat-inactivated oral probiotic formulation being tested as a postbiotic for use in consumer-friendly formats like toothpaste or foods for oral health,” they add.

Dentisani, as a postbiotic, has demonstrated a decrease in dental plaque and gingival inflammation, a significant increase in salivary ammonia and calcium levels and a beneficial shift in bacterial composition.

Furthermore, AB-Biotics are tapping into the rising field of fermented foods with a product that helps consumers to make healthy sustainable yogurts enriched with probiotics by fermenting milk at home.

“We closely monitor what consumers are looking for and the pain points manufacturers and health professionals face. For many, the demand is for more consumer-friendly formats beyond capsules and sachets.”

At stand J110 at Vitafoods, the company will bring child-friendly aluminum tubes, which ensure probiotics in liquid form are dispensed carefully with no product loss while maintaining stability.

“Trends come and go. Our innovations are based on consistent market challenges and global matters that we can truly help with using our science and technology. We don’t aim to reduce symptoms of serious diseases because of trends but instead to improve quality of life and offer long-term solutions,” they conclude.

By Beatrice Wihlander